VEGFA and neoplasm: (5), after using a chemotherapy regimen postoperatively, the median overall survival is extended to 12–14 months; 3) Surgery + targeted immunotherapy: receptor tyrosine kinase inhibitors can target and bind to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting tumor angiogenesis and tumor cell proliferation.